If you are currently looking into stocks which may have gained momentum yesterday then it could be a good move to consider taking a look at the Northwest Biotherapeutics (OTCMKTS:NWBO) stock.
Trading Data
On Tuesday, NWBO stock moved up 2.04% to $0.6451 with more than 4.24 million shares, compared to volume of 1.71 million shares. The stock moved within a range of $0.6201 – 0.6801 after opening trade at $0.6370.
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA
The company, which is currently best known for developing DCVax, announced yesterday that the UK Medicines and Healthcare Products Regulatory Agency awarded the approval for its Pediatric Investigation Plan or PIP. It is a significant new development for the company and hence, it was perhaps not a surprise that the stock gained momentum yesterday. The regulatory approval of the PIP is a precondition if the company is to seek approval of any new medicines that it develops.
The approved PIP is going to be made up of two separate clinical trials. Both the trials are going to involved 24 patients in each and the patients are going to be treated with DCVax-L. As per the regulatory laws in the United Kingdom, if a medicine is being developed for adults, then it must also be tested for potentially treating pediatric patients. Now that the stock has gained momentum, it is going to be interesting to see if it can manage to clock gains today or not.
Technical Data
NWBO stock is trading below the 20-Day and 50-Day Moving averages of $0.6581 and $0.67 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.81. The company has a total market capitalization of $634.77 million. The stock is up 2% over the past month.
